A Phase II, Randomized, Double-Blind, Placebo Controlled, Multi-Center Study to Evaluate the Effects of LCI699 on Cortisol in Patients With Hypertension.
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2014
At a glance
- Drugs Osilodrostat (Primary)
- Indications Essential hypertension
- Focus Adverse reactions
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 01 Sep 2012 Results published in the Journal of Clinical Hypertension (Greenwich).
- 24 Feb 2011 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History